KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Convertible Debt (2016 - 2025)

Travere Therapeutics' Convertible Debt history spans 14 years, with the latest figure at $311.7 million for Q4 2025.

  • For Q4 2025, Convertible Debt changed 0.46% year-over-year to $311.7 million; the TTM value through Dec 2025 reached $311.7 million, changed 0.46%, while the annual FY2025 figure was $311.7 million, 0.46% changed from the prior year.
  • Convertible Debt reached $311.7 million in Q4 2025 per TVTX's latest filing, roughly flat from $311.4 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $378.1 million in Q2 2024 to a low of $218.1 million in Q1 2021.
  • Average Convertible Debt over 5 years is $325.8 million, with a median of $343.0 million recorded in 2022.
  • Peak YoY movement for Convertible Debt: soared 71.65% in 2022, then decreased 17.75% in 2025.
  • A 5-year view of Convertible Debt shows it stood at $226.6 million in 2021, then skyrocketed by 65.74% to $375.5 million in 2022, then rose by 0.46% to $377.3 million in 2023, then dropped by 17.75% to $310.3 million in 2024, then rose by 0.46% to $311.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Convertible Debt are $311.7 million (Q4 2025), $311.4 million (Q3 2025), and $311.0 million (Q2 2025).